Brief: Synthaverse To Update And Internationalize Development Strategy

Synthaverse SA

03/07/2025 16:32

July 3 (Reuters) - Synthaverse SA SVEP.WA:

RESOLVES TO INTERNATIONALIZE AND UPDATE COMPANY'S DEVELOPMENT STRATEGY

FOCUSES ON INNOVATION AND COMMERCIALIZATION OF FLAGSHIP PRODUCTS ONKO BGC, ANTI-TUBERCULOSIS VACCINE BCG, DISTREPTASE

IMPLEMENTATION OF ONKO BCG PRODUCTION PLANT AND RESEARCH AND DEVELOPMENT CENTER INCREASES PRODUCTION CAPACITY SIXFOLD

EXPECTS TO COMPLETE OPERATIONAL QUALIFICATION IN COMING WEEKS IN ONKO BGC AND RESEARCH AND DEVELOPMENT CENTER

FIRST SALES EXPECTED AT BEGINNING OF 2027 AFTER 18-MONTH REGULATORY PROCESS

TO DEVELOP BCG VACCINE FOR UNICEF MARKET

TO ENTER HIGH-MARGIN THERAPEUTIC AREAS INCLUDING ONCOLOGY

TO SEEK ADDITIONAL FINANCING OF AROUND PLN 23 MILLION FOR DEVELOPMENT PROJECTS AND WORKING CAPITAL

Source text: ID:nEM71p8G1a

Further company coverage: SVEP.WA

 (Reporting by Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))